Advertisement

Structural bowel damage in quiescent Crohn’s disease

Published:February 12, 2017DOI:https://doi.org/10.1016/j.dld.2017.02.001

      Abstract

      Background

      Crohn’s disease is associated with accumulation of progressive structural bowel damage (SBD) leading to the development of stenotic and penetrating complications. The data pertaining to the course of progression of SBD is scarce. The Lemann index (LI) is a novel tool for evaluation of SBD that incorporates pan-enteric clinical, endoscopic and imaging data.

      Aims

      To evaluate the progression of SBD in quiescent CD patients.

      Methods

      Patients with known quiescent small bowel Crohn’s disease (CD) for at least 3 months (CDAI < 220) were prospectively recruited and underwent repeated magnetic resonance enterographies (MRE) and video capsule endoscopies (VCE). Patients were assessed for SBD on initial and follow-up evaluation using relevant clinicopathological data, MRE and VCE results. Significant structural bowel damage (SBD) was identified as LI > 4.8, and progression of SBD as LI > 0.3.

      Results

      Sixty one patients were enrolled in the study. Significant SBD was detected 13 (21.4%) on enrollment. Duration of disease (p = 0.036) and history of CD-related surgery (p = 0.0001) were associated with significant BD. Forty one patients underwent a follow-up MRE (14.8 ± 2.5 months apart). LI was similar at baseline and follow-up. There was a negligible change in LI between the evaluations.

      Conclusions

      In patients with quiescent Crohn’s disease, structural bowel damage was stable over a median of 14 months follow-up.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cosnes J.
        • Cattan S.
        • Blain A.
        • et al.
        Long-term evolution of disease behavior of Crohn's disease.
        Inflammatory Bowel Diseases. 2002; 8: 244-250
        • Pariente B.
        • Mary J.Y.
        • Danese S.
        • et al.
        Development of the Lemann index to assess digestive tract damage in patients with Crohn's disease.
        Gastroenterology. 2015; 148 (52–63.e3)
        • Pariente B.
        • Cosnes J.
        • Danese S.
        • et al.
        Development of the Crohn's disease digestive damage score, the Lemann score.
        Inflammatory Bowel Diseases. 2011; 17: 1415-1422
        • Gilletta C.
        • Lewin M.
        • Bourrier A.
        • et al.
        Changes in the Lemann index values during the first years of Crohn's Disease.
        Clinical Gastroenterology and Hepatology. 2015; 13 (. e3): 1633-1640
        • Bodini G.
        • Giannini E.G.
        • De Maria C.
        • et al.
        Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease: a study performed using the Lemann Index.
        Digestive and Liver Disease. 2016;
        • Fiorino G.
        • Bonifacio C.
        • Peyrin-Biroulet L.
        • et al.
        Preventing collateral damage in crohn's disease: the Lemann index.
        Journal of Crohn's & Colitis. 2016; 10: 495-500
        • Fiorino G.
        • Bonifacio C.
        • Allocca M.
        • et al.
        Bowel damage as assessed by the Lemann index is reversible on anti-TNF therapy for Crohn's disease.
        Journal of Crohn's & Colitis. 2015; 9: 633-639
        • Peyrin-Biroulet L.
        • Loftus Jr., E.V.
        • Colombel J.F.
        • et al.
        Early Crohn disease: a proposed definition for use in disease-modification trials.
        Gut. 2010; 59: 141-147
        • Safroneeva E.
        • Vavricka S.R.
        • Fournier N.
        • et al.
        Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.
        Alimentary Pharmacology & Therapeutics. 2015; 42: 977-989
        • Magro F.
        • Rodrigues-Pinto E.
        • Coelho R.
        • et al.
        Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression.
        The American Journal of Gastroenterology. 2014; 109: 1026-1036
        • Kopylov U.
        • Eliakim R.
        The Lemann index—a glance through the window of opportunity?.
        Journal of Crohn's & Colitis. 2016;
        • Danese S.
        • Fiorino G.
        • Fernandes C.
        • et al.
        Catching the therapeutic window of opportunity in early Crohn's disease.
        Current Drug Targets. 2014; 15: 1056-1063
        • Kopylov U.
        • Yablecovitch D.
        • Lahat A.
        • et al.
        Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn's disease using biomarkers, capsule endoscopy, and imaging.
        The American Journal of Gastroenterology. 2015; 110: 1316-1323
        • Greener T.
        • Klang E.
        • Yablecovitch D.
        • et al.
        The impact of magnetic resonance enterography and capsule endoscopy on the re-classification of disease in patients with known Crohn's disease: a prospective Israeli IBD Research Nucleus (IIRN) study.
        Journal of Crohn's & Colitis. 2016; 10: 525-531
        • Peyrin-Biroulet L.
        • Sandborn W.
        • Sands B.E.
        • et al.
        Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target.
        The American Journal of Gastroenterology. 2015; 110: 1324-1338
        • Shrot S.
        • Konen E.
        • Hertz M.
        • et al.
        Magnetic resonance enterography: 4 years experience in a tertiary medical center.
        The Israel Medical Association Journal: IMAJ. 2011; 13: 172-177
        • Gralnek I.M.
        • Defranchis R.
        • Seidman E.
        • et al.
        Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change.
        Alimentary Pharmacology & Therapeutics. 2008; 27: 146-154
        • Cosnes J.
        • Gower-Rousseau C.
        • Seksik P.
        • et al.
        Epidemiology and natural history of inflammatory bowel diseases.
        Gastroenterology. 2011; 140: 1785-1794
        • Pineton de Chambrun G.
        • Blanc P.
        • Peyrin-Biroulet L.
        Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.
        Expert Review of Gastroenterology & Hepatology. 2016; : 1-13
        • Bhattacharya A.
        • Rao B.B.
        • Koutroubakis I.E.
        • et al.
        Silent Crohn's disease predicts increased bowel damage during multiyear follow-up: the consequences of under-reporting active inflammation.
        Inflammatory Bowel Diseases. 2016; 22: 2665-2671
        • Rispo A.
        • Imperatore N.
        • Testa A.
        • et al.
        Bowel damage in Crohn's disease: direct comparison of ultrasonography-based and magnetic resonance-based Lemann index.
        Inflammatory Bowel Diseases. 2017; 23: 143-151